Publication:
Risk and Management of Patients with Cancer and Heart Disease

dc.contributor.authorHill, Loreena
dc.date.accessioned2023-08-17T05:42:49Z
dc.date.available2023-08-17T05:42:49Z
dc.date.issued2023
dc.description.abstractAbstract: Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure.en_US
dc.identifier.other410-2023.02
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1331
dc.language.isoenen_US
dc.subjectCardiotoxicityen_US
dc.subjectAnthracyclineen_US
dc.subjectRisk Stratificationen_US
dc.subjectHeart Failureen_US
dc.titleRisk and Management of Patients with Cancer and Heart Diseaseen_US
dc.typeArticleen_US
dspace.entity.typePublicationen_US

Files